Cardiovascular effects of sulphonylureas: Role of KATP channels

Diabetes, Obesity and Metabolism

Volumn 2, Issue 2, 2000, Pages 67-73

  Howes, Laurence G ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Cardiovascular; Sulphonylureas; Type 2 diabetes

Indexed keywords

DIAZOXIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM CHANNEL; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE;

ANIMAL TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; ELECTRIC ACTIVITY; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MORBIDITY; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 0034527370     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00047.x     Document Type: Review

References (60)

1. Central role of sodium in hypertension in diabetic subjects
2. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects
3. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes
4. The ABCs of ATP-sensitive potassium channels: More pieces of the puzzle
5. Molecular biology of the b-cell ATP-sensitive K+ channel
6. Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion
7. + channel
8. + channel in cardiac muscle
9. Cardiac ATP-sensitive K+ channels: Regulation by intracellular nucleotides and potassium opening drugs
10. Membrane hyperpolarization is a mechanism of endothelium-dependent cerebral vasodilation
11. Endothelium-dependent hyperpolarising factor (EDHF)
12. Prostanoid-induced contractions are blocked by sulfonylureas
13. Antidiabetic sulfonylureas relax isolated rabbit coronary arteries
14. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts
15. Cardiovascular effects of conventional sulfonylureas and glimepiride
16. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide
17. Vascular pharmacology of ATP-sensitive K-channels: Interactions between glyburide and K-channel-openers
18. Ischaemic preconditioning limits infarct size in the rat heart
19. Myocardial protection with preconditioning
20. + channel blocker
21. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features
22. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: A prospective study
23. The ATP-regulated potassium channel in ischemia-reperfusion injury
24. ATP-sensitive potassium channels and myocardial ischemia: Why do they open?
25. An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning
26. Adenosine and anti-infarct effects of preconditioning
27. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine
28. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
29. Limitation offarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide
30. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels
31. Sulfonylureas and ischaemic preconditioning
32. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium
33. Effects oftracoronary cromakalim on postischaemic contractile function and action potential duration
34. Effect of potassium on the action of the K+ATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia
35. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats
36. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat
37. Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart
38. The effects of ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs
39. Potassium channel openers and blockers: Do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
40. + loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea
41. Effects of HMR 1883 on coronary flow and ventricular fibrillation in isolated guinea pig hearts
42. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart
43. Inotropic effects of tolbutamide in man
44. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin dependent diabetes mellitus
45. ATP channels and N omega-nitro-L-arginine on coronary perfusion pressure in isolated Langendorff-perfused guinea pigs hearts
46. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs
47. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo
48. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients
49. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans
50. Activation of ATP-sensitive potassium channels contributes to reactive hyperemia in humans
51. Acute effects of glyburide on the regulation of peripheral blood flow in normal humans
52. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics
53. The effects of glibenclamide on blood pressure and cardiovascular responsiveness in NIDDMs
54. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in non-insulin dependent diabetes
55. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
56. Clinical biostatistics. XXXV: The persistent clinical failures and fallacies of the UGDP study
57. The Achilles heel of the University Group Diabetes Program
58. Adverse cardiovascular effects of sulphonylurea drugs: Clinical significance
59. Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia
60. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients